This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celldex Therapeutics' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Celldex Therapeutics, Inc. (CLDX)

Q2 2012 Earnings Call

August 10, 2012, 08:30 am ET

Executives

Anthony Marucci - President & CEO

Chip Catlin - SVP & CFO

Tom Davis - SVP & Chief Medical Officer

Tibor Keler - SVP & Chief Scientific Officer

Analysts

Jonathan Aschoff - Brean Murray

Mara Goldstein - Cantor Fitzgerald

Biren Amin - Jefferies

Joe Pantginis - Roth Capital Partners

Mani Mohindru - ThinkEquity

Steve Brozak - WBB Securities

Presentation



Operator

Good morning and welcome to Celldex Therapeutics second quarter and 2012 update conference call. My name is Chanel and I will be your operator on today's call.

Before we begin our discussion, I have been asked to caution listeners that today's speakers will be making forward-looking statements. Such statements reflect current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

Certain of the factors that might cause Celldex’s actual results to differ materially from those in the forward-looking statements include those set forth under the heading Risk Factors and management’s discussion and analysis of financial condition and results of operations and Celldex’s annual report on Form 10-K quarterly reports on Form 10-Q and its current report on Form 8-K as well as those described in Celldex’s press release and filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in the entirety by this cautionary notice. You should carefully review all these factors and be aware that there maybe other factors that could cause these differences. These forward-looking statements are based on information, plans and estimates as of this call and Celldex does not promise to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other things.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs